BACKGROUND:Barrett's esophagus is the major risk factor for esophageal adenocarcinoma, the incidence of which is increasing rapidly in the Western world. Aminolevulinic acid for photodynamic therapy (ALA-PDT) is effective in the treatment of Barrett's esophagus, but controversy exists regarding optimum ALA dosage. The aim of this study was to establish the optimum dosage regime for ALA-PDT for Barrett's esophagus. METHODS:Twenty-five patients with Barrett's esophagus were randomized to receive 30 (low-dose) or 60 (high-dose) mg/kg oral ALA at 4 or 6 h or 30 mg/kg in two fractions 4 and 6 h before PDT. PDT was standardized using red (635 nm) light. Biopsy specimens were taken for protoporphyrin IX (PpIX) quantification. Endoscopy was repeated 4 weeks later. RESULTS: All patients showed a macroscopic response, with squamous re-epithelialization. This response was greatest in the 30 mg/kg and fractionated ALA groups. There was no significant difference in response between dosing 4 or 6 h prior to PDT. Tissue levels of PpIX were similar for all dosage groups and were not predictive of clinical response. Side effects were more common with the higher dose of ALA. CONCLUSION: Low-dose ALA-PDT appears to be a safe protocol for the ablation of Barrett's esophagus.
RCT Entities:
BACKGROUND: Barrett's esophagus is the major risk factor for esophageal adenocarcinoma, the incidence of which is increasing rapidly in the Western world. Aminolevulinic acid for photodynamic therapy (ALA-PDT) is effective in the treatment of Barrett's esophagus, but controversy exists regarding optimum ALA dosage. The aim of this study was to establish the optimum dosage regime for ALA-PDT for Barrett's esophagus. METHODS: Twenty-five patients with Barrett's esophagus were randomized to receive 30 (low-dose) or 60 (high-dose) mg/kg oral ALA at 4 or 6 h or 30 mg/kg in two fractions 4 and 6 h before PDT. PDT was standardized using red (635 nm) light. Biopsy specimens were taken for protoporphyrin IX (PpIX) quantification. Endoscopy was repeated 4 weeks later. RESULTS: All patients showed a macroscopic response, with squamous re-epithelialization. This response was greatest in the 30 mg/kg and fractionated ALA groups. There was no significant difference in response between dosing 4 or 6 h prior to PDT. Tissue levels of PpIX were similar for all dosage groups and were not predictive of clinical response. Side effects were more common with the higher dose of ALA. CONCLUSION: Low-dose ALA-PDT appears to be a safe protocol for the ablation of Barrett's esophagus.
Authors: R Ackroyd; N Brown; D Vernon; D Roberts; T Stephenson; S Marcus; C Stoddard; M Reed Journal: Photochem Photobiol Date: 1999-10 Impact factor: 3.421
Authors: R Ackroyd; N J Brown; M F Davis; T J Stephenson; S L Marcus; C J Stoddard; A G Johnson; M W Reed Journal: Gut Date: 2000-11 Impact factor: 23.059
Authors: Petra Hinnen; Felix W M de Rooij; Wim C J Hop; Annie Edixhoven; Herman van Dekken; J H Paul Wilson; Peter D Siersema Journal: J Photochem Photobiol B Date: 2002-08 Impact factor: 6.252
Authors: J Regula; A J MacRobert; A Gorchein; G A Buonaccorsi; S M Thorpe; G M Spencer; A R Hatfield; S G Bown Journal: Gut Date: 1995-01 Impact factor: 23.059
Authors: Gary D Mackenzie; Jason M Dunn; C R Selvasekar; C Alexander Mosse; Sally M Thorpe; Marco R Novelli; Stephen G Bown; Laurence B Lovat Journal: Lasers Med Sci Date: 2008-12-05 Impact factor: 3.161
Authors: Gary D Mackenzie; Neil F Jamieson; Marco R Novelli; C Alexander Mosse; Benjamin R Clark; Sally M Thorpe; Stephen G Bown; Laurence B Lovat Journal: Lasers Med Sci Date: 2007-07-03 Impact factor: 3.161
Authors: Stuart J Wong; Bruce Campbell; Becky Massey; Denis P Lynch; Ezra E W Cohen; Elizabeth Blair; Rebecca Selle; Julia Shklovskaya; Borko D Jovanovic; Silvia Skripkauskas; Alexander Dew; Peter Kulesza; Vamsi Parimi; Raymond C Bergan; Eva Szabo Journal: Oral Oncol Date: 2013-07-08 Impact factor: 5.337